A conference call to discuss the year's results and recent developments in the company's business will be webcast live tomorrow, at 8:00am Eastern Daylight Time/12 noon GMT/1pm British Summer Time (details below). DeCODE genetics Announces Full-year 2008 Financial Results REYKJAVIK, Iceland, / - / -- deCODE genetics (Nasdaq:DCGN) today announced its consolidated financial results for the quarter and year ended. In killian 2009 the company sold its auction rate securities (ARS) for $11.0 million in cash which the company has been using to finance its operating activities.

However we need to obtain additional funds both to continue operations in the near term and to capture the longer term value of our products. The company believes it has sufficient resources to sustain operations only into the second quarter of this year.

"deCODE has employed its capabilities in medicinal chemistry, structural biology and human genetics to develop a unique portfolio of products and intellectual property with significant commercial potential. To address this need, the management team and.

At , the company had liquid funds available for operating activities, comprised of cash and cash equivalents together with current investments, of $3.7 million, compared to $64.2 million at December 31, 2007.